Summary
The sample was submitted by Noxy Labs, with testing ordered on 1 August 2024 and completed on 16 August 2024. While these results confirm the product’s potency, readers should note that manufacturer-funded testing may involve potential biases. Manufacturers often submit select batches that meet their high-quality standards, which may not fully reflect the consistency of products available to consumers. To ensure transparency, these results would benefit from independent third-party validation across multiple batches.
This report is published for educational and harm reduction purposes, providing critical insights for consumers seeking to verify product quality.
Detailed Report
Product Overview
- Manufacturer: Noxy Labs
- Product Name: Boldenone 200mg
- Active Ingredient: Boldenone Undecylenate
- Batch Number: 15TBK1
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #46708
- Testing Ordered: 1 August 2024
- Sample Received: 6 August 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Noxy Labs
- Analysis Paid For By: Noxy Labs
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 206.95 mg/ml
- Accuracy: 103.5% (3.5% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/46708_ZZ8A2YQB5CWF
- Originally Published: https://thinksteroids.com/community/posts/3324084/
Evaluation of Manufacturer-Submitted Testing
This analysis confirms that Boldenone 200mg by Noxy Labs exceeds its labeled claim, reflecting strong quality control for this batch. However, since the sample was submitted and funded by the manufacturer, potential biases should be considered. Manufacturer-funded tests may not fully represent product consistency across all batches. Independent testing, ideally funded and procured by third-party entities, remains critical to ensuring transparency and consumer trust.
Conclusion
The lab report demonstrates that Boldenone 200mg contains 206.95 mg/ml of Boldenone Undecylenate, confirming a slight overdosage of 3.5%. While this result highlights the accuracy of this batch, independent third-party testing remains essential to verify consistency across the product line. This report serves as an educational tool to promote harm reduction and informed decision-making for consumers.
Disclaimer
This report is published for educational and harm reduction purposes. Manufacturer-funded testing may involve inherent biases; however, it can still provide useful data when critically assessed alongside third-party or independent results. Readers are encouraged to use this information responsibly.
